Archive:
Apr 21, 2025, 12:00 AM
Neoadjuvant treatment with cobimetinib and atezolizumab±vemurafenib associated with low rate of distant metastasis in patients with high-risk stage III melanoma
Background: Neoadjuvant treatment has become standard for patients with high-risk operable stage III melanoma, but the optimal regimen is unknown. Targeted therapy approaches yield high pathological …
Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy
Background: Cell-free, circulating tumour DNA (ctDNA) is an established measure of minimal residual disease; however, it is not utilised in melanoma management. We investigated whether ctDNA measurem…